Viatris Inc Stock Forecast for 2023 - 2025 - 2030

Updated on 11/29/2023

Stock Rating
8
Price Target
$11.50
Consensus
Neutral
Upside
25.82%
Analysts
8
Stock Rating
8
Upside
25.82%
Analysts
8
Price Target
$11.50

Viatris Inc Stock Forecast and Price Target

The average price target for Viatris Inc's stock of $11.50 recently provided by eight leading analysts would represent a 25.82% upside from its last closing price if reached. This potential increase is based on a high estimate of $14.00 and a low estimate of $9.00. You may be interested in rivals even if you aren't interested in Viatris Inc stock.

$11.50

25.82% Upside

Hold
Hold

Viatris Inc Fair Value Forecast for 2023 - 2025 - 2030

In the last three years, Viatris Inc's Price has fallen from $18.87 to $14.30 – a 24.21% decrease. For next year, analysts predict Fair Value of $14.69, which would mean an increase of 2.69%. Over the next eight years, experts predict that Viatris Inc's Fair Value will grow at a rate of 23.88%.

2023 Fair Value Forecast
$14.69
2024 Fair Value Forecast
$14.69
2025 Fair Value Forecast
$14.82
2026 Fair Value Forecast
$15.54
2027 Fair Value Forecast
$16.44
2028 Fair Value Forecast
$16.91
2029 Fair Value Forecast
$17.34
2030 Fair Value Forecast
$17.72
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
LLY Stock Forecast Eli Lilly & Co Outperform 16
$591.60 Buy/Sell $594.01 9.87%
JNJ Stock Forecast Johnson & Johnson Outperform 10
$151.63 Buy/Sell $176.14 13.43%
MRK Stock Forecast Merck Outperform 5
$100.18 Buy/Sell $123.75 24.78%
PFE Stock Forecast Pfizer Inc Outperform 3
$29.69 Buy/Sell $40.55 26.31%
BMY Stock Forecast Bristol-Myers Squibb Co Outperform 2
$48.92 Buy/Sell $64.26 25.72%

Viatris Inc Revenue Forecast for 2023 - 2025 - 2030

In the last three years, Viatris Inc's Revenue has grown by 41.41%, rising from $11.50B to $16.26B. For next year, analysts predict Revenue of $16.63B, which would mean an increase of 2.27%. Over the next eight years, experts predict that Viatris Inc's Revenue will grow at a rate of 5.15%.

2023 Rev Forecast
$16.63B
2024 Rev Forecast
$16.51B
2025 Rev Forecast
$16.36B
2026 Rev Forecast
$17.11B
2027 Rev Forecast
$16.69B
2028 Rev Forecast
$16.82B
2029 Rev Forecast
$16.95B
2030 Rev Forecast
$17.10B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
VRTX Stock Forecast Vertex Pharmaceuticals Inc Outperform 15
$347.04 Buy/Sell $395.90 12.38%
REGN Stock Forecast Regeneron Pharmaceuticals Inc Outperform 2
$801.14 Buy/Sell $796.73 14.09%
ZTS Stock Forecast Zoetis Inc Outperform 18
$176.97 Buy/Sell $217.57 18.66%

Viatris Inc Dividend per Share Forecast for 2023 - 2025 - 2030

In the last year, Viatris Inc's Dividend per Share has grown by 6.67%, rising from $0.45 to $0.48. For next year, analysts predict Dividend per Share of $0.51, which would mean an increase of 6.25%. In 2030, professionals predict that Viatris Inc's Dividend per Share will decrease by 17.52%, to $0.40.

2023 DPS Forecast
$0.51
2024 DPS Forecast
$0.58
2025 DPS Forecast
$0.64
2026 DPS Forecast
$0.00
2027 DPS Forecast
$0.60
2028 DPS Forecast
$0.58
2029 DPS Forecast
$0.59
2030 DPS Forecast
$0.40
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ALNY Stock Forecast Alnylam Pharmaceuticals Inc Outperform 7
$161.36 Buy/Sell $245.24 42.54%
BAX Stock Forecast Baxter International Inc Outperform 17
$36.34 Buy/Sell $45.50 22.45%
UTHR Stock Forecast United Therapeutics Corp Outperform 12
$230.39 Buy/Sell $278.82 30.21%

Viatris Inc Free Cash Flow Forecast for 2023 - 2025 - 2030

Viatris Inc's Free Cash Flow has grown In the last three years, rising from $1.59B to $2.71B – a growth of 70.36%. In the next year, analysts believe that Free Cash Flow will reach $3.62B – an increase of 33.53%. For the next eight years, experts predict that Viatris Inc's Free Cash Flow will grow at a rate of 52.20%.

2023 FCF Forecast
$3.62B
2024 FCF Forecast
$3.71B
2025 FCF Forecast
$3.46B
2026 FCF Forecast
$4.21B
2027 FCF Forecast
$3.69B
2028 FCF Forecast
$3.82B
2029 FCF Forecast
$4.01B
2030 FCF Forecast
$4.12B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
IONS Stock Forecast Ionis Pharmaceuticals Inc Outperform 9
$48.34 Buy/Sell $51.20 24.12%
CTLT Stock Forecast Catalent Outperform 15
$39.46 Buy/Sell $49.29 21.64%
BCPC Stock Forecast Balchem Outperform 18
$122.71 Buy/Sell $145.00 22.24%

Viatris Inc Net Income Forecast for 2023 - 2025 - 2030

In the last three years, Viatris Inc's Net Income has grown, rising from $16.80M to $2.08B – a growth of 12272.62%. In the next year, analysts believe that Net Income will reach $4.15B – an increase of 99.70%. For the next eight years, the forecast is for Net Income to grow by 144.30%.

2023 NI Forecast
$4.15B
2024 NI Forecast
$4.18B
2025 NI Forecast
$4.22B
2026 NI Forecast
$4.43B
2027 NI Forecast
$4.70B
2028 NI Forecast
$4.83B
2029 NI Forecast
$4.96B
2030 NI Forecast
$5.08B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
MDGL Stock Forecast Madrigal Pharmaceuticals Outperform 4
$190.94 Buy/Sell $170.08 73.09%
NEOG Stock Forecast Neogen Outperform 16
$16.60 Buy/Sell $37.00 34.04%
CYTK Stock Forecast Cytokinetics Inc Outperform 10
$31.22 Buy/Sell $61.75 92.18%

Viatris Inc EBITDA Forecast for 2023 - 2025 - 2030

Viatris Inc's EBITDA has seen impressive growth In the last three years, rising from $3.26B to $5.70B – a growth of 74.84%. In the next year, analysts believe that EBITDA will reach $5.99B – an increase of 5.05%. For the next eight years, the forecast is for EBITDA to grow by 26.10%.

2023 EBITDA Forecast
$5.99B
2024 EBITDA Forecast
$5.95B
2025 EBITDA Forecast
$5.98B
2026 EBITDA Forecast
$6.28B
2027 EBITDA Forecast
$6.60B
2028 EBITDA Forecast
$6.78B
2029 EBITDA Forecast
$6.97B
2030 EBITDA Forecast
$7.19B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
AMPH Stock Forecast Amphastar Pharmaceuticals Outperform 14
$54.41 Buy/Sell $69.00 21.30%
CORT Stock Forecast Corcept Therapeutics Outperform 16
$25.45 Buy/Sell $0.00 41.45%
INDV Stock Forecast Indivior PLC Buy 14
£12.38 Buy/Sell £3.79 134.25%

Viatris Inc EBIT Forecast for 2023 - 2025 - 2030

In the last three years, Viatris Inc's EBIT has grown by 100.20%, rising from $1.42B to $2.85B. For the next year, analysts predict that EBIT will reach $5.60B – an increase of 96.65%. Over the next eight years, experts believe that Viatris Inc's EBIT will grow at a rate of 122.20%.

2023 EBIT Forecast
$5.60B
2024 EBIT Forecast
$5.54B
2025 EBIT Forecast
$5.53B
2026 EBIT Forecast
$5.75B
2027 EBIT Forecast
$5.98B
2028 EBIT Forecast
$6.09B
2029 EBIT Forecast
$6.21B
2030 EBIT Forecast
$6.33B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
TGTX Stock Forecast TG Therapeutics Outperform 9
$12.63 Buy/Sell $26.83 90.02%
CPRX Stock Forecast Catalyst Pharmaceuticals Outperform 16
$14.21 Buy/Sell $23.30 75.93%
IRWD Stock Forecast Ironwood Pharmaceuticals Outperform 14
$9.68 Buy/Sell $17.40 106.61%

Viatris Inc EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last three years, Viatris Inc's EPS has fallen from $4.42 to $3.35 – a 24.21% decrease. For next year, analysts predict EPS of $3.44, which would mean an increase of 2.69%. Over the next eight years, experts predict that Viatris Inc's EPS will grow at a rate of 23.88%.

2023 EPS Forecast
$3.44
2024 EPS Forecast
$3.44
2025 EPS Forecast
$3.47
2026 EPS Forecast
$3.64
2027 EPS Forecast
$3.85
2028 EPS Forecast
$3.96
2029 EPS Forecast
$4.06
2030 EPS Forecast
$4.15
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
SUPN Stock Forecast Supernus Pharmaceuticals Outperform 16
$26.97 Buy/Sell $41.00 53.87%
ARPO Stock Forecast Aerpio Pharmaceuticals - 6
$30.30 Buy/Sell $0.00 -100.00%
PCRX Stock Forecast Pacira BioSciences Outperform 16
$27.50 Buy/Sell $49.11 81.82%